Temozolomide + Radiation Therapy
Treatment for Brain And Central Nervous System Cancer
Typical Dosage: RT: 60 Gy in 30 fractions; TMZ: 75 mg/m2 daily concurrently, then 150-200 mg/m2 daily for 5 days every 28 days
Effectiveness
70%
Safety Score
30%
Clinical Trials
141
Participants
35K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
RT: 60 Gy in 30 fractions; TMZ: 75 mg/m2 daily concurrently, then 150-200 mg/m2 daily for 5 days every 28 days
Time to Effect
6-12 months
Treatment Duration
6-12 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
10(Treat 10 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30,000
Monitoring:$18,000
Side Effect Mgmt:$8,000
Total Annual:$56,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$150,000/QALY
QALYs Gained
0.19
Outcome-Based Costs
Cost per Responder
$160,000
Cost per Remission
$1,120,000
Comparison vs Radiation Therapy alone
Cost Difference
+$38,000/year
More expensive
QALY Difference
+0.19 QALYs
Better outcomes
Dominance
No dominance
Temozolomide + Radiation Therapy Outcomes
for Brain And Central Nervous System Cancer
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
16 completed trials for Temozolomide + Radiation Therapy in Brain And Central Nervous System Cancer
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
NCT00114140COMPLETEDPHASE2
136 participants
INTERVENTIONAL
Phoenix, United States +46 more
Started: Jan 1, 2005
Radiation Therapy or Temozolomide in Treating Patients With Gliomas
NCT00182819COMPLETEDPHASE3
709 participants
INTERVENTIONAL
Randwick, Australia +88 more
Started: Jul 1, 2005
Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00006353COMPLETEDPHASE3
575 participants
INTERVENTIONAL
Calgary, Canada +15 more
Started: Jul 1, 2000
Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme
NCT00820963COMPLETEDPHASE3
70 participants
INTERVENTIONAL
Lyon, France
Started: Jul 1, 2006
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
NCT00003464COMPLETEDPHASE2
50 participants
INTERVENTIONAL
Durham, United States
Started: Sep 1, 1997
Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas
NCT00033280COMPLETEDPHASE2
42 participants
INTERVENTIONAL
Mobile, United States +38 more
Started: Jul 1, 2002
Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
NCT00998010COMPLETEDPHASE2
24 participants
INTERVENTIONAL
Los Angeles, United States
Started: Oct 3, 2011
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
NCT00553150COMPLETEDPHASE1, PHASE2
122 participants
INTERVENTIONAL
Scottsdale, United States +177 more
Started: Mar 1, 2009
Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma
NCT00028795COMPLETEDPHASE2
170 participants
INTERVENTIONAL
Birmingham, United States +229 more
Started: Dec 1, 2002
Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00869401COMPLETEDPHASE1, PHASE2
217 participants
INTERVENTIONAL
Hartford, United States +206 more
Started: Jun 1, 2009
Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00974987COMPLETEDPHASE2
32 participants
INTERVENTIONAL
Takatsuki, Japan
Started: Sep 1, 2009
Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00128700COMPLETEDPHASE1, PHASE2
20 participants
INTERVENTIONAL
Leuven, Belgium +4 more
Started: Jun 1, 2005
Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00099125COMPLETEDPHASE2
170 participants
INTERVENTIONAL
Phoenix, United States +117 more
Started: Nov 1, 2004
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
NCT01013285COMPLETEDPHASE2
70 participants
INTERVENTIONAL
Los Angeles, United States
Started: Jun 1, 2006
Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
NCT00068250COMPLETEDPHASE1, PHASE2
60 participants
INTERVENTIONAL
Jacksonville, United States +25 more
Started: Jul 1, 2003
Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma
NCT00720564COMPLETEDPHASE1
18 participants
INTERVENTIONAL
Duarte, United States
Started: Apr 1, 2008
Showing 20 of 141 total trials